ArticleClinical cardiology2008
Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction.
Article in Clinical cardiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 82 citations in OpenAlex.
- Using proximity extension proteomics assay to identify biomarkers associated with infarct size and ejection fraction after ST-elevation myocardial infarction.Scientific reports · 2020Trial
- Evaluation of MMP-9, IL-6, TNF-α levels and peripheral blood mononuclear cells genes expression of MMP-9 and TIMP-1 in Iranian patients with coronary artery disease.Journal of cardiovascular and thoracic research · 2023Article
- IL-6, IL-1RA and Resistin as Predictors of Left Ventricular Remodelling and Major Adverse Cardiac Events in Patients with Acute ST Elevation Myocardial Infarction.Diagnostics (Basel, Switzerland) · 2022Article
- Construction of a Joint Prediction Model for the Occurrence of Ischemic Stroke and Acute Myocardial Infarction Based on Bioinformatic Analysis.Disease markers · 2022Article
- The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease.Journal of cardiovascular translational research · 2021Review
- The utility of inflammation and platelet biomarkers in patients with acute coronary syndromes.Saudi journal of biological sciences · 2018Article
- Serum MMP-9 Diagnostics, Prognostics, and Activation in Acute Coronary Syndrome and Its Recurrence.Journal of cardiovascular translational research · 2018Article
- Systemic Inflammatory Response Syndrome is an Independent Predictor of One-Year Mortality in Patients with Acute Myocardial Infarction.Acta Cardiologica Sinica · 2017Article
- Acute phase of aortic dissection: a pilot study on CD40L, MPO, and MMP-1, -2, 9 and TIMP-1 circulating levels in elderly patients.Immunity & ageing : I & A · 2016Article
- Serial measurement of lipid profile and inflammatory markers in patients with acute myocardial infarction.EXCLI journal · 2015Article
- Interleukin-33, matrix metalloproteinase-9, and tissue inhibitor [corrected] of matrix metalloproteinase-1 in myocardial infarction.The Korean journal of internal medicine · 2013Article
- The history of matrix metalloproteinases: milestones, myths, and misperceptions.American journal of physiology. Heart and circulatory physiology · 2012Review
- Correlations between serum inflammation factors and left ventricular remodeling in acute ST segment elevation myocardial infarction.Yonsei medical journal · 2012Article
- Better cognitive and physical performance is associated with higher blood pressure in centenarians.The journal of nutrition, health & aging · 2011Article
- Plasma concentrations of soluble CD40 ligand in smokers with acute myocardial infarction: a pilot study.Heart and vessels · 2011Article
- Nonalcoholic fatty liver disease and the coronary artery disease.Digestive diseases and sciences · 2011Review
- Prognostic value of interleukin-6 during a 3-year follow-up in patients with acute ST-segment elevation myocardial infarction.Heart and vessels · 2009Article
- The co-evolution of our understanding of CD40 and inflammation.Diabetologia · 2009Article
- Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction.Clinical cardiology · 2009Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtherosclerosis is widely accepted as a chronic inflammatory disease. Research paid much attention to sensitive specific serum biomarkers for vulnerable plaques. The markers not only serve as diagnostic tools for the identification of patients with acute coronary syndrome (ACS), but also help us to identify high-risk patients. However, the existing data are limited and have been conflicting. HYPOTHESIS: Circulating interleukin-6 (IL-6), soluble CD40 ligand (sCD40L), metalloproteinase-9 (MMP-9), and tissue inhibitor of metalloproteinase-1 (TIMP-1) might correlate with the onset and the cardiac mortality of patients with ST-segment elevation myocardial infarction (STEMI).
methodsSerum levels of IL-6, sCD40L, MMP-9, and TIMP-1 were measured by sandwich enzyme-linked immunosorbent assay (ELISA) in 263 patients with STEMI and 262 age- and gender-matched control subjects without coronary artery disease (CAD). The patients with STEMI were then followed prospectively for 24 mo for the occurrence of cardiac mortality.
resultsCompared with the control subjects, patients with STEMI exhibited higher levels of IL-6 (p<0.001), sCD40L (p<0.001), MMP-9 (p<0.001), TIMP-1 (p=0.045), and MMP-9/TIMP-1 ratio (p=0.007). Significant and positive correlations between MMP-9 and TIMP-1 (r=0.610, p<or=0.001]), IL-6 and creatine kinase (CK) (r=0.159, p=0.022), and IL-6 and Troponin-I (TnI) (r=0.141, p=0.042) were observed by Spearman's correlations analysis. Logistic regression analysis revealed that IL-6 significantly and independently correlated with the occurrence of STEMI, and IL-6 was an independent predictor for cardiac mortality during a 24-mo follow-up in patients with STEMI.
conclusionThe present study indicates that elevated admission level of IL-6, but not of sCD40L, MMP-9, or TIMP-1, might indicate the onset of STEMI, and could provide prognostic value for future cardiac mortality within 2 y in patients with STEMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.